Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
April 23, 2024Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
April 23, 2024Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
April 22, 2024Medical Communications Emblaveo, European Commission, Immunology, Pfizer
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult …
Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder
April 22, 2024Research and Development Kaerus Bioscience, Neurolentech, Neurology, neurodevelopmental disorders, neurology
Neurolentech has announced that it has entered into a technology access partnership with Kaerus Bioscience, with the aim of driving …
Ardena announces €20m expansion following first GMP approval
April 19, 2024Manufacturing and Production Ardena, Pharmacy, facility, manufacturing
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new …
Roche’s Alecensa approved by FDA as lung cancer treatment
April 19, 2024Medical Communications FDA, Oncology, Roche, lung cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …
GSK shares results from phase 3 trial for gonorrhoea treatment
April 18, 2024Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
April 18, 2024Research and Development Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or …
Medincell and AbbVie enter agreement for development of next-generation injectables
April 17, 2024Research and Development AbbVie, Immunology, Medincell, collaboration
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation …
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
April 17, 2024Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …
Novartis shares new data about Fabhalta for IgAN treatment
April 16, 2024Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …
GSK’s meningococcal vaccine candidate accepted for FDA review
April 16, 2024Medical Communications FDA, GSK, Immunology, meningococcal
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
Lipocine announces results from phase 2 trial for obesity drug
April 12, 2024Research and Development Lipocine, Obesity, clinical trial, weight loss
Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …
Baxter expands US portfolio with new injectables
April 12, 2024Medical Communications Pharmacy, baxter, injectables, product launch
Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in …
Vertex to acquire Alpine Immune Sciences for $4.9bn
April 11, 2024Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy
Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …
NICE recommends migraine treatment for NHS use
April 11, 2024Medical Communications NHS, NICE, Neurology, migraine
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
April 10, 2024Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
April 10, 2024Research and Development FDA, Oncology, Oryzon, lung cancer
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
